{
    "nct_id": "NCT04237623",
    "official_title": "Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post-Infusion of T-Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells and With Post Transplant Cyclophosphamide",
    "inclusion_criteria": "* Availability of 5/10 to 8/10 matched related donor\n* KPS >/= 70%\n* CML, AML, MDS, ALL, CLL, HD, NHL, MPS/CMML, MM, any other hematologic condition deemed an eligible indication for allogeneic transplant by the treating center\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 78 Years",
    "exclusion_criteria": "* Poor cardiac, pulmonary, liver, and renal function\n* HIV-positive\n* Patients who have a debilitating medical or psychiatric illness that would preclude them from giving informed consent\n* History of severe or serious allergic reaction to human GM-CSF or yeast-derived products",
    "miscellaneous_criteria": ""
}